What the retatrutide approval tracker is for

Retatrutide is the first medicine on The Dose Club with an approval tracker page in place of a price table. People ask about it, and the answer to "how much does it cost" is that there is no lawful UK price, because the medicine has no UK licence. This article explains what the tracker shows, what it deliberately leaves out and why.

What a marketing authorisation is

In the UK a medicine can be marketed only once the Medicines and Healthcare products Regulatory Agency (MHRA) has granted it a marketing authorisation, usually called a licence. The MHRA grants one after assessing the evidence on the medicine's quality, safety and efficacy, and the approved patient information leaflet and summary of product characteristics are part of it. Wegovy and Mounjaro hold UK marketing authorisations. Retatrutide does not.

What the tracker shows

• The licence status, in one line: no UK marketing authorisation.
• What is known about the medicine from published work, kept to what is settled, such as that it is a once weekly injection in development.
• A timeline of regulatory steps as far as the MHRA has published one. There is none yet, and the page says so, with a note that it is updated when the MHRA publishes a decision.
• A warning about products sold online as research peptides.
• The date the page was last reviewed. The team is prompted to look again at any tracker that has not been reviewed for 90 days.

What it never shows

• Prices. There is no UK pharmacy price for a medicine no UK pharmacy can lawfully supply, and inventing a hypothetical one would be advertising an unlicensed medicine, which is prohibited.
• Vendor names. No seller is named, and the admin tools refuse to publish a tracker that names any pharmacy on the provider registry.
• Suggested launch dates or pricing that does not exist. The page describes what is, and says plainly what is not known.
• Trial results summarised as if they were settled. Results announced by a manufacturer are not a licence. What the regulator accepts, and the wording it approves for the leaflet, is what a tracker records, and until then the page says that trial results are not summarised.

Research peptides

Products marketed as "research peptides" or "for research use only" are not licensed medicines. They are not made or checked to medicine standards, nobody independent can verify what a vial contains, and no regulator has assessed them for use in people. A product labelled retatrutide from such a seller has no regulator behind the label. The MHRA publishes warnings about buying medicines from unregulated sellers, and the Dose Club community filters block posts that offer, source or link to these products, including the vocabulary that goes with them.

If the position changes

If the MHRA grants retatrutide a marketing authorisation, the tracker records the decision and the date. Prices appear only after that, and only once pharmacies registered with the General Pharmaceutical Council stock it, at which point the tracker gives way to a price tab built the same way as the Wegovy and Mounjaro tabs. Nothing on the site will describe a price before then.

In the app

The Dose Club app lists retatrutide as investigational, with user entered doses only and an acknowledgement before it can be selected. Its level chart shows a percentage of your own peak. An estimate in milligrams needs a published bioavailability figure, and none exists for retatrutide. The app never suggests a dose for any medicine, licensed or not.

Sources

• Medicines and Healthcare products Regulatory Agency, marketing authorisations and warnings about unregulated sellers: gov.uk
• CAP Code rule 12.11, Committee of Advertising Practice
• The Dose Club retatrutide approval tracker (page on this site)

This article is information, not medical advice. Talk to your prescriber about your treatment.